New drug mimics natural protein to calm overactive immune system in nerve disease
NCT ID NCT07027111
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing a new drug called NVG-2089 in 60 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system attacks nerves. The drug is designed to mimic a natural protein (IVIg) to reduce inflammation and improve nerve function. Researchers are checking how safe it is and whether it helps patients feel better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NVG-2089 (a drug designed to mimic IVIg protein to calm the immune system)
What this could lead to
If it works, this could provide a new treatment option for people with CIDP, potentially reducing nerve damage and improving daily function.
What could go wrong
This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nuvig Site
Denton, Texas, 76208, United States